2020 ICER Assessments

The Institute for Clinical Economic Review (ICER) conducts cost effectiveness studies for insurers using the cost-per-QALY methodology. ICER provides guidance on its website for patients and patient advocates to provide direct input related to their experiences with the disease. Click here to provide patient input. Click here to view the topics and deadlines. All of ICER’s current assessments have been put on hold for 2-3 months in response to COVID-19. We will continue to update below deadlines as we receive more information.

  • Ulcerative Colitis: Draft Evidence Report and Draft Voting Questions AVAILABLE. Comment period open through 7/29/2020. Meeting 9/24/2020: CTAF will convene to deliberate and vote on evidence presented in ICER’s report on ulcerative colitis therapies.
  • Cystic Fibrosis: Evidence Report and Response to Comments AVAILABLE. Meeting August 27, 2020: CTAF will convene to deliberate and vote on evidence presented in ICER’s report on treatments for cystic fibrosis.
  • Sickle Cell Disease: Evidence Report and Responses to Comments AVAILABLE. Meeting POSTPONED: New England CEPAC will convene to deliberate and vote on evidence presented in ICER’s report on treatments for sickle cell disease.
  • Non-Alcoholic Steatohepatitis: 7/21/2020: Evidence Report and Responses to Comments. Meeting was cancelled due to FDA stating that current efficacy and safety data are not sufficient for accelerated approval.
  • Hemophilia A: Model Analysis Plan AVAILABLE. 8/26/2020: Draft Evidence Report.
  • Bladder Cancer: Revised Scoping Document AVAILABLE. 7/14/2020: Research Protocol.
  • Opioids: Digital Apps: Revised Scoping Document AVAILABLE. 7/14/2020: Research Protocol.
  • Opioids: Supervised Injection Centers: Revised Scoping Document AVAILABLE. 7/21/2020: Research Protocol.
  • High Cholesterol: Draft Scoping Document Available. Public Comments Open through 7/24/2020.
  • Anemia in Chronic Kidney Disease: Open input period through Wednesday, 7/15/2020.
  • Unsupported Price Increase Assessment: Protocol Available. Public input through 7/17/2020.